Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2017; 37(02): 186-192
DOI: 10.1055/s-0037-1601887
DOI: 10.1055/s-0037-1601887
Review Article
Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy
Further Information
Publication History
Publication Date:
16 May 2017 (online)
Abstract
Impulsive and compulsive behaviors in Parkinson's disease (PD) patients are most often attributed to dopamine agonist therapy; dysregulation of the mesocorticolimbic system accounts for this behavioral phenotype. The clinical presentation is commonly termed impulse control disorder (ICD): Behaviors include hypersexuality, compulsive eating, shopping, pathological gambling, and compulsive hobby participation. However, not all PD individuals taking dopamine agonists develop these behavioral changes. In this review, the authors focus on the similarities between the phenotypic presentation of ICDs with that of other reward-based behavioral disorders, including binge eating disorder, pathological gambling, and substance use disorders. With this comparison, we emphasize that the transition from an impulsive to compulsive behavior likely follows a ventral to dorsal striatal pattern, where an altered dopaminergic reward system underlies the emergence of these problematic behaviors. The authors discuss the neurobiological similarities between these latter disorders and ICDs, emphasizing similar pathophysiological processes and discussing treatment options that have potential for translation to PD patients.
-
References
- 1 Voon V, Gao J, Brezing C , et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011; 134 (Pt 5): 1438-1446
- 2 Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 2011; 24 (4) 324-330
- 3 Macmahon D, Macphee G. Dopamine agonists and impulse control disorders in Parkinson's disease. Prog Neurol Psychiatry 2008; 12 (9) 5-9
- 4 Claassen DO, Kanoff K, Wylie SA. Dopamine agonists and impulse control disorders in Parkinson's disease. US Neurol 2013; 9 (2) 13-16
- 5 Lim S-Y, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008; 1142: 85-107
- 6 Shimo Y, Hattori N. Underlying mechanisms of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson's disease. J Neurol Disord Stroke 2014; 2 (3) 1-4
- 7 Ranaldi R. Dopamine and reward seeking: the role of ventral tegmental area. Rev Neurosci 2014; 25 (5) 621-630
- 8 Yun IA, Wakabayashi KT, Fields HL, Nicola SM. The ventral tegmental area is required for the behavioral and nucleus accumbens neuronal firing responses to incentive cues. J Neurosci 2004; 24 (12) 2923-2933
- 9 Luo AH, Tahsili-Fahadan P, Wise RA, Lupica CR, Aston-Jones G. Linking context with reward: a functional circuit from hippocampal CA3 to ventral tegmental area. Science 2011; 333 (6040): 353-357
- 10 Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985; 35 (8) 1215-1218
- 11 Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A , et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014; 85 (8) 840-844
- 12 Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 1993; 43 (3 Pt 1): 505-508
- 13 Arabia G, Grossardt BR, Colligan RC , et al. Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 2010; 75 (4) 349-357
- 14 Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61 (4) 502-510
- 15 Rabinak CA, Nirenberg MJ ; CA R. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67 (1) 58-63
- 16 Evans AH, Pavese N, Lawrence AD , et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59 (5) 852-858
- 17 Keeler JF, Pretsell DO, Robbins TW. Functional implications of dopamine D1 vs. D2 receptors: A ‘prepare and select’ model of the striatal direct vs. indirect pathways. Neuroscience 2014; 282: 156-175
- 18 West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002; 22 (1) 294-304
- 19 Hikida T, Kimura K, Wada N, Funabiki K, Nakanishi S. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 2010; 66 (6) 896-907
- 20 Beninger RJ, Miller R. Dopamine D1-like receptors and reward-related incentive learning. Neurosci Biobehav Rev 1998; 22 (2) 335-345
- 21 Steeves TDL, Miyasaki J, Zurowski M , et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132 (Pt 5): 1376-1385
- 22 Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 2002; 26 (3) 321-352
- 23 Proulx CD, Hikosaka O, Malinow R. Reward processing by the lateral habenula in normal and depressive behaviors. Nat Neurosci 2014; 17 (9) 1146-1152
- 24 Lawson RP, Seymour B, Loh E , et al. The habenula encodes negative motivational value associated with primary punishment in humans. Proc Natl Acad Sci U S A 2014; 111 (32) 11858-11863
- 25 Carlezon Jr WAJ, Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 2009; 56 (Suppl. 01) 122-132
- 26 Pujara MS, Philippi CL, Motzkin JC, Baskaya MK, Koenigs M. Ventromedial prefrontal cortex damage is associated with decreased ventral striatum volume and response to reward. J Neurosci 2016; 36 (18) 5047-5054
- 27 Behan B, Stone A, Garavan H. Right prefrontal and ventral striatum interactions underlying impulsive choice and impulsive responding. Hum Brain Mapp 2015; 36 (1) 187-198
- 28 Beck A, Schlagenhauf F, Wüstenberg T , et al. Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics. Biol Psychiatry 2009; 66 (8) 734-742
- 29 Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005; 8 (11) 1481-1489
- 30 Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc London B Biol Sci 2008; 363 (1507): 3125-3135
- 31 Burton AC, Nakamura K, Roesch MR. From ventral-medial to dorsal-lateral striatum: neural correlates of reward-guided decision-making. Neurobiol Learn Mem 2015; 117: 51-59
- 32 Volkow ND, Wang GJ, Telang F , et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26 (24) 6583-6588
- 33 Vollstädt-Klein S, Wichert S, Rabinstein J , et al. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 2010; 105 (10) 1741-1749
- 34 American Psychiatric Association. Feeding and eating disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 5th ed.. DSM Library. American Psychiatric Association; 2013
- 35 Hudson JI, Hiripi E, Pope Jr HGJ, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61 (3) 348-358
- 36 Manwaring JL, Green L, Myerson J, Strube MJ, Wilfley DE. Discounting of various types of rewards by women with and without binge eating disorder: evidence for general rather than specific differences. Psychol Rec 2011; 61 (4) 561-582
- 37 Kessler RM, Hutson PH, Herman BK, Potenza MN. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev 2016; 63: 223-238
- 38 Balodis IM, Kober H, Worhunsky PD , et al. Monetary reward processing in obese individuals with and without binge eating disorder. Biol Psychiatry 2013; 73 (9) 877-886
- 39 Woolley JD, Gorno-Tempini M-L, Seeley WW , et al. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology 2007; 69 (14) 1424-1433
- 40 Yang B-Z, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum Mol Genet 2007; 16 (23) 2844-2853
- 41 Davis C, Levitan RD, Kaplan AS , et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 2007; 32 (10) 2199-2206
- 42 Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry 2005; 57 (3) 301-309
- 43 Pearlstein T, Spurell E, Hohlstein LA , et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Women Ment Health 2003; 6 (2) 147-151
- 44 McElroy SL, Arnold LM, Shapira NA , et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160 (2) 255-261
- 45 Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat 2006; 2 (4) 475-488
- 46 Citrome L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 2015; 69 (4) 410-421
- 47 Goudriaan AE, Oosterlaan J, de Beurs E, Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 2004; 28 (2) 123-141
- 48 Santangelo G, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord 2013; 19 (7) 645-653
- 49 Welte JW, Barnes GM, Wieczorek WF, Tidwell M-CO, Parker JC. Risk factors for pathological gambling. Addict Behav 2004; 29 (2) 323-335
- 50 Rizeanu S. Pathological gambling and depression. Procedia Soc Behav Sci 2013; 78: 501-505
- 51 Potenza MN, Leung H-C, Blumberg HP , et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160 (11) 1990-1994
- 52 Reuter J, Raedler T, Rose M, Hand I, Gläscher J, Büchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8 (2) 147-148
- 53 Balodis IM, Kober H, Worhunsky PD, Stevens MC, Pearlson GD, Potenza MN. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry 2012; 71 (8) 749-757
- 54 Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 2009; 24 (6) 899-905
- 55 Blaszczynski A, Nower L. A pathways model of problem and pathological gambling. Addiction 2002; 97 (5) 487-499
- 56 Blum K, Sheridan PJ, Wood RC , et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996; 89 (7) 396-400
- 57 Blanco C, Orensanz-Muñoz L, Blanco-Jerez C, Saiz-Ruiz J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 1996; 153 (1) 119-121
- 58 Comings DE, Gade-Andavolu R, Gonzalez N , et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001; 60 (2) 107-116
- 59 Ibañez A, Perez de Castro I, Fernandez-Piqueras J, Blanco C, Saiz-Ruiz J. Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Mol Psychiatry 2000; 5 (1) 105-109
- 60 Ibáñez A, Blanco C, Perez de Castro I, Fernandez-Piqueras J, Sáiz-Ruiz J. Genetics of pathological gambling. J Gambl Stud 2003; 19 (1) 11-22
- 61 Ladouceur R, Jacques C, Ferland F, Giroux I. Prevalence of problem gambling: a replication study 7 years later. Can J Psychiatry 1999; 44 (8) 802-804
- 62 Grant JE, Potenza MN, Hollander E , et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163 (2) 303-312
- 63 Papay K, Xie SX, Stern M , et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014; 83 (9) 826-833
- 64 Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28 (1) 6-10
- 65 Black DW, Shaw MC, Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (5) 1191-1194
- 66 Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol 2009; 23 (6) 660-671
- 67 Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry 2009; 22 (1) 69-74
- 68 Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62 (6) 652-657
- 69 Hernandez L, Hoebel BG. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 1988; 42 (18) 1705-1712
- 70 Di Ciano P, Everitt BJ. Direct interactions between the basolateral amygdala and nucleus accumbens core underlie cocaine-seeking behavior by rats. J Neurosci 2004; 24 (32) 7167-7173
- 71 Everitt BJ, Robbins TW. From the ventral to the dorsal striatum: devolving views
of their roles in drug addiction. Neurosci Biobehav Rev 2013; 37 (9 Pt A): 1946-1954
MissingFormLabel
- 72 Dackis CA, Gold MS. Pharmacological approaches to cocaine addiction. J Subst Abuse Treat 1985; 2 (3) 139-145
- 73 Gorelick DA, Wilkins JN. Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels. Drug Alcohol Depend 2006; 81 (2) 189-195
- 74 Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs 2005; 19 (1) 13-25
- 75 Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55 (2) 122-125
- 76 Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50 (3) 261-265
- 77 Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend 2003; 71 (2) 207-211
- 78 Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011; 69 (4) 695-712
- 79 Heiden P, Heinz A, Romanczuk-Seiferth N. Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?. Eur J Neurosci 2017; 45 (1) 67-72
- 80 Soloff PH, Lynch KG, Moss HB. Serotonin, impulsivity, and alcohol use disorders in the older adolescent: a psychobiological study. Alcohol Clin Exp Res 2000; 24 (11) 1609-1619
- 81 Hinckers AS, Laucht M, Schmidt MH , et al. Low level of response to alcohol as associated with serotonin transporter genotype and high alcohol intake in adolescents. Biol Psychiatry 2006; 60 (3) 282-287
- 82 Ferrari PF, Palanza P, Parmigiani S, de Almeida RMM, Miczek KA. Serotonin and aggressive behavior in rodents and nonhuman primates: predispositions and plasticity. Eur J Pharmacol 2005; 526 (1-3): 259-273
- 83 Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 2008; 13 (5) 383-395
- 84 Dalley JW, Roiser JP. Dopamine, serotonin and impulsivity. Neuroscience 2012; 215: 42-58
- 85 Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159 (12) 2048-2054
- 86 Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006; 18 (3) 377-383
- 87 Demetriades P, Rickards H, Cavanna AE. Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis 2011; 2011: 658415
- 88 Brunenberg EJL, Moeskops P, Backes WH , et al. Structural and resting state functional connectivity of the subthalamic nucleus: identification of motor STN parts and the hyperdirect pathway. PLoS One 2012; 7 (6) e39061
- 89 Greenhouse I, Gould S, Houser M, Aron AR. Stimulation of contacts in ventral but not dorsal subthalamic nucleus normalizes response switching in Parkinson's disease. Neuropsychologia 2013; 51 (7) 1302-1309
- 90 Rodriguez-Oroz MC, López-Azcárate J, Garcia-Garcia D , et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2010; 134: 36-49
- 91 Wylie SA, Ridderinkhof KR, Elias WJ , et al. Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain 2010; 133 (12) 3611 LP-3624 LP
- 92 Hälbig TD, Tse W, Frisina PG , et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009; 16 (4) 493-497